Orlov S. Nicole Schaeffer Sells 4,999 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) insider Orlov S. Nicole Schaeffer sold 4,999 shares of the business’s stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $67.81, for a total transaction of $338,982.19. Following the completion of the sale, the insider now directly owns 115,879 shares of the company’s stock, valued at approximately $7,857,754.99. This trade represents a 4.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Insmed Stock Performance

Shares of NASDAQ:INSM opened at $68.12 on Friday. The company has a market capitalization of $12.41 billion, a price-to-earnings ratio of -12.19 and a beta of 0.84. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The firm has a 50 day moving average of $71.57 and a 200 day moving average of $73.12.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). The business had revenue of $92.82 million for the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business’s revenue for the quarter was up 22.9% on a year-over-year basis. During the same period in the previous year, the company posted ($1.06) earnings per share. On average, sell-side analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

INSM has been the subject of several research reports. Wells Fargo & Company boosted their price objective on shares of Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. Morgan Stanley boosted their price objective on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Jefferies Financial Group initiated coverage on shares of Insmed in a research report on Tuesday, May 13th. They issued a “buy” rating and a $105.00 price objective for the company. Guggenheim reissued a “buy” rating and issued a $101.00 price objective on shares of Insmed in a research report on Tuesday, February 25th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, Insmed has an average rating of “Moderate Buy” and a consensus price target of $94.63.

Hedge Funds Weigh In On Insmed

Large investors have recently made changes to their positions in the business. Cullen Frost Bankers Inc. increased its position in shares of Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 221 shares in the last quarter. Elequin Capital LP acquired a new position in shares of Insmed during the fourth quarter worth $28,000. Steward Partners Investment Advisory LLC increased its position in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 163 shares in the last quarter. NBC Securities Inc. acquired a new position in shares of Insmed during the first quarter worth $49,000. Finally, V Square Quantitative Management LLC increased its position in shares of Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 248 shares in the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.